Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.63 |
| ▸ | BCHE | P06276 | 7/20 | 0.55 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8845548 | 0.89 | ACHE (0.51) | ACHEBCHEHDAC1HDAC6 | |
| SCHEMBL16494058 | 0.89 | ACHE (0.61) | ACHEBCHEADRB2ADRB1ADRB3 | |
| SCHEMBL16494808 | 0.87 | ACHE (0.62) | ACHEADRB2ADRB1ADRB3 | |
| SCHEMBL16494086 | 0.87 | ACHE (0.68) | ACHEBCHE | |
| SCHEMBL16494294 | 0.87 | ACHE (0.59) | ACHEBCHEADRB2ADRB1ADRB3 | |
| SCHEMBL16494238 | 0.86 | ACHE (0.58) | ACHEADRB2ADRB1ADRB3HDAC1 | |
| SCHEMBL16494464 | 0.86 | ACHE (0.58) | ACHEADRB2ADRB1ADRB3HDAC1 | |
| SCHEMBL16494526 | 0.85 | ACHE (0.60) | ACHEADRB2ADRB1ADRB3 | |
| SCHEMBL16494443 | 0.85 | ACHE (0.60) | ACHEBCHEADRB2ADRB1ADRB3 | |
| SCHEMBL16494293 | 0.85 | ACHE (0.57) | ACHEBCHEADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | claimed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | claimed |
| EP-2394990-A1 | INDOLINE DERIVATIVES | Kyoto University (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-20110294850-A1 | INDOLINE DERIVATIVES | TOKYO INSTITUTE OF TECHNOLOGY (JP) | 2011-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294850-A1 | INDOLINE DERIVATIVES | BCHE, ACHE, INMT | ACHE 2/4885BCHE 1/4885ADRB2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.